文献速递神经肌肉病

乙胺嘧啶显著降低SOD1突变型ALS患者脑脊液Cu/Zn超氧化物歧化酶

Pyrimethamine significantly lowers cerebrospinal fluid Cu/Zn superoxide dismutase in amyotrophic lateral sclerosis patients with SOD1 mutations.
PubMed 文献 · Ann Neurol · 2017-06-09

这项多中心开放标签9个月剂量探索研究纳入32例SOD1突变家族性ALS患者,评估乙胺嘧啶降低脑脊液SOD1的安全性和有效性。线性混合效应模型显示,第6次访视脑脊液SOD1平均降低13.5%(95%CI 8.4-18.5,p<0.001),第9次访视平均降低10.5%(95%CI 5.2-15.8,p<0.001)。乙胺嘧啶安全且耐受良好。

要点

  • 乙胺嘧啶在SOD1突变ALS患者中安全且耐受良好。
  • 乙胺嘧啶可显著降低脑脊液总SOD1蛋白含量。
  • 尚需长期研究评估临床疗效。

核心结论

  • 乙胺嘧啶在ALS患者中安全且耐受良好。
  • 乙胺嘧啶能显著降低不同SOD1突变所致ALS患者脑脊液总SOD1蛋白含量。
  • 需进一步长期研究评估临床疗效。

研究设计与样本

  • 多中心(5个中心)、开放标签、为期9个月的剂量探索研究。
  • 纳入32例携带SOD1突变的家族性ALS患者,24例完成6次访视(18周),21例完成全部访视。
  • 所有参与者接受3次腰椎穿刺、抽血、肌力与运动功能及生活质量临床评估和不良事件评估。
  • 检测红细胞和脑脊液SOD1水平,以及血浆和脑脊液乙胺嘧啶浓度。

主要发现

  • 线性混合效应模型显示第6次访视脑脊液SOD1显著降低(p<0.001),平均降低13.5%(95%CI 8.4-18.5)。
  • 第9次访视脑脊液SOD1显著降低(p<0.001),平均降低10.5%(95%CI 5.2-15.8)。

临床怎么用

  • 对于SOD1突变型ALS患者,乙胺嘧啶可作为降低脑脊液SOD1的候选治疗,但临床疗效尚待长期研究确认。

局限性

  • 开放标签设计,未设安慰剂对照。
  • 样本量较小(32例),部分患者未完成全部访视。
  • 研究时长9个月,未评估长期临床疗效。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Cu/Zn superoxide dismutase (SOD1) reduction prolongs survival in SOD1-transgenic animal models. Pyrimethamine produces dose-dependent SOD1 reduction in cell culture systems. A previous phase 1 trial showed pyrimethamine lowers SOD1 levels in leukocytes in patients with SOD1 mutations. This study investigated whether pyrimethamine lowered SOD1 levels in the cerebrospinal fluid (CSF) in patients carrying SOD1 mutations linked to familial amyotrophic lateral sclerosis (fALS/SOD1). METHODS: A multicenter (5 sites), open-label, 9-month-duration, dose-ranging study was undertaken to determine the safety and efficacy of pyrimethamine to lower SOD1 levels in the CSF in fALS/SOD1. All participants underwent 3 lumbar punctures, blood draw, clinical assessment of strength, motor function, quality of life, and adverse effect assessments. SOD1 levels were measured in erythrocytes and CSF. Pyrimethamine was measured in plasma and CSF. Appel ALS score, ALS Functional Rating Scale-Revised, and McGill Quality of Life Single-Item Scale were measured at screening, visit 6, and visit 9. RESULTS: We enrolled 32 patients; 24 completed 6 visits (18 weeks), and 21 completed all study visits. A linear mixed effects model showed a significant reduction in CSF SOD1 at visit 6 (p < 0.001) with a mean reduction of 13.5% (95% confidence interval [CI] = 8.4-18.5) and at visit 9 (p < 0.001) with a mean reduction of 10.5% (95% CI = 5.2-15.8). INTERPRETATION: Pyrimethamine is safe and well tolerated in ALS. Pyrimethamine is capable of producing a significant reduction in total CSF SOD1 protein content in patients with ALS caused by different SOD1 mutations. Further long-term studies are warranted to assess clinical efficacy. Ann Neurol 2017;81:837-848.

来源:Ann Neurol,查看原文。版权归原作者所有。

引用

  1. Lange DJ, Shahbazi M, Silani V, et al. Pyrimethamine significantly lowers cerebrospinal fluid Cu/Zn superoxide dismutase in amyotrophic lateral sclerosis patients with SOD1 mutations. Ann Neurol. 2017. PMID: 28480639. doi:10.1002/ana.24950

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。